Investigation of the clinical safety and efficacy of favipiravir (Avigan tablets) in patients with novel or re-emerging influenza virus infections
Not Applicable
- Conditions
- ovel or re-emerging influenza infections
- Registration Number
- JPRN-jRCT1080223849
- Lead Sponsor
- FUJIFILM Toyama Chemical Co., Ltd. (Former Toyama Chemical Co., Ltd.)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- preinitiation
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
novel or re-emerging influenza infections who take favipiravir (Avigan tablets) and any gender welcome.
Exclusion Criteria
Pregnant women or women suspected of being pregnant
Patients with known hypersensitivity to favipiravir or any of its excipients
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy<br>Evaluation of therapy
- Secondary Outcome Measures
Name Time Method